NRx Pharmaceuticals Company Insiders
| NRXPW Stock | USD 0.18 0.03 20.00% |
NRx Pharmaceuticals employs about 13 people. The company is managed by 13 executives with a total tenure of roughly 31 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Recap of NRx Pharmaceuticals' management performance can provide insight into the venture performance.
NRx |
NRx Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (1.1597) % which means that it has lost $1.1597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.8261) %, meaning that it generated substantial loss on money invested by shareholders. NRx Pharmaceuticals' management efficiency ratios could be used to measure how well NRx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.NRx Pharmaceuticals Workforce Comparison
NRx Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 224. NRx Pharmaceuticals holds roughly 13.0 in number of employees claiming about 6% of equities under Health Care industry.
NRx Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NRx Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on NRx Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, NRx Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Javitt Daniel C. over six months ago Disposition of 33018 shares by Javitt Daniel C. of NRx Pharmaceuticals at 1.0523 subject to Rule 16b-3 | ||
Kim Bennett over six months ago Insider Trading |
NRx Pharmaceuticals Notable Stakeholders
A NRx Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NRx Pharmaceuticals often face trade-offs trying to please all of them. NRx Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NRx Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stephen Esq | CEO Secretary | Profile | |
| Richard Narido | Principal CFO | Profile | |
| Suzanne Messere | Investor Relations | Profile | |
| Robert MIM | Chief Operations | Profile | |
| Michael Kunz | Gen Sec | Profile | |
| Molly Cogan | Sr Affairs | Profile | |
| Seth Voorhees | CFO Treasurer | Profile | |
| Dennis McBride | Chief Scientist | Profile | |
| Matthew Duffy | Chief Therapeutics | Profile | |
| Prof Javitt | CoFounder Board | Profile | |
| Riccardo Panicucci | Chief Officer | Profile | |
| MPH MD | Chief CoFounder | Profile | |
| Philip Lavin | Chief Methodologist | Profile |
About NRx Pharmaceuticals Management Performance
The success or failure of an entity such as NRx Pharmaceuticals often depends on how effective the management is. NRx Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Please note, the imprecision that can be found in NRx Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NRx Pharmaceuticals. Check NRx Pharmaceuticals' Beneish M Score to see the likelihood of NRx Pharmaceuticals' management manipulating its earnings.
NRx Pharmaceuticals Workforce Analysis
Traditionally, organizations such as NRx Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NRx Pharmaceuticals within its industry.NRx Pharmaceuticals Manpower Efficiency
Return on NRx Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.3M | |
| Net Loss Per Executive | 2.3M |
Additional Tools for NRx Stock Analysis
When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.